@article{94667d94bf514d058303a1f345cef710,
title = "Polymorphisms in the wilms tumor gene are associated with interindividual variations in rubella virus-specific cellular immunity after measles-mumps-rubella II vaccination",
abstract = " Rubella vaccination induces widely variable immune responses in vaccine recipients. While rubella vaccination is effective at inducing immunity to rubella infection in most subjects, up to 5% of individuals do not achieve or maintain long-term protective immunity. To expand upon our previous work identifying genetic polymorphisms that are associated with these interindividual differences in humoral immunity to rubella virus, we performed a genome-wide association study in a large cohort of 1843 subjects to discover single-nucleotide polymorphisms (SNPs) associated with rubella virus-specific cellular immune responses. We identified SNPs in the Wilms tumor protein gene (WT1) that were significantly associated (P < 5 x 10 -8 ) with interindividual variations in rubella-specific interleukin 6 secretion from subjects' peripheral blood mononuclear cells postvaccination. No SNPs were found to be significantly associated with variations in rubella-specific interferon-γ secretion. Our findings demonstrate that genetic polymorphisms in the WT1 gene in subjects of European ancestry are associated with interindividual differences in rubella virus-specific cellular immunity after measles-mumps-rubella II vaccination. ",
keywords = "Genetic, Genome-wide association study, IL-6, Immunity, Measles-mumps-rubella vaccine, Polymorphisms, Rubella, Rubella virus, SNP",
author = "Voigt, {Emily A.} and Haralambieva, {Iana H.} and Larrabee, {Beth L.} and Kennedy, {Richard B.} and Ovsyannikova, {Inna G.} and Schaid, {Daniel J.} and Poland, {Gregory A.}",
note = "Funding Information: Financial support. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the NIH (award number R37AI048793, which recently received an NIH MERIT award, and award number R01AI033144). Potential conflicts of interest. G. A. P. is the chair of a safety evaluation committee for novel investigational vaccine trials being conducted by Merck Research Laboratories; and offers consultative advice on vaccine development to Merck & Co Inc, Avianax, Dynavax, Novartis Vaccines and Therapeutics, Seqirus, Protein Sciences, and Adjuvance Technologies. G. A. P. and I. G. O. hold 3 patents related to vaccinia and measles peptide research. R. B. K. has received funding from Merck Research Laboratories to study waning immunity to mumps vaccine. These activities and this research have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic conflict of interest policies. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Publisher Copyright: {\textcopyright} The Author(s) 2017.",
year = "2018",
month = feb,
day = "15",
doi = "10.1093/infdis/jix538",
language = "English (US)",
volume = "217",
pages = "560--566",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",
}